KRTL Holding Group Business Summary

KRTL Holding Group Inc (KRTL) operates as a diversified holding company generating revenue through a multi-stream model that includes pharmaceutical product sales, international trade consulting fees, and the distribution of active pharmaceutical ingredients (APIs). The company’s primary business segments are organized under specialized subsidiaries: KRTL Biotech (biopharmaceutical R&D), KRTL International (global consulting and distribution), KRTL MedHealth (healthcare infrastructure), and Camelot’s Nutrition (consumer health products). A significant portion of its 2026 revenue growth is driven by the integration of its Bolivian subsidiary, SIGMA, which provides GMP-certified manufacturing and a portfolio of essential medicines. KRTL competes directly with firms such as CTT Pharmaceutical Holdings, Sonoma Pharmaceuticals, and Processa Pharmaceuticals. Within this landscape, KRTL positions itself as a regulatory-focused disruptor, leveraging its FDA-registered facilities and cross-border trade frameworks to bridge the gap between South American manufacturing and U.S. market demand. Leadership is spearheaded by Founder and CEO Cesar Leonardo Herrera, a veteran executive with over 26 years of experience across finance, mining, and international pharmaceutical brokering, known for navigating complex regulatory landscapes like the KFDA and FDA. Supporting him is Mario “Tony” Hernandez, who serves as Secretary and Treasurer, bringing over two decades of expertise in corporate structure and compliance. The biotechnology division is led by Dr. Stefan Kasian, who was appointed CEO of KRTL Biotech in early 2026 to drive product commercialization, alongside Chief Science Officer Dr. Malcolm Leissring. The company’s strategic direction is further bolstered by a board that includes Patricia Wilstermann, the CEO of SIGMA, following a landmark merger that consolidated over $20 million in annual pharmaceutical revenue. This leadership team is complemented by an advisory board featuring former executives from Nasdaq-listed companies, focusing on institutional investor readiness and SEC Rule 15c2-11 compliance.